Medpace Holdings, Inc. - Common Stock (MEDP)
Industrials › Services-Commercial Physical & Biological Research
Price History
Feb 9, 2026 — Mar 31, 2026Investment Snapshot
- Trading 533% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 89.8% with 17.5% net margin
- Revenue growing at 20% annually
Medpace Holdings, Inc. - Common Stock (MEDP) is a Industrials company operating in Services-Commercial Physical & Biological Research, listed on the NASDAQ , with a market capitalisation of $13.1 billion . Key value metrics: P/E ratio 31.7, P/B ratio 28.46, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Medpace Holdings, Inc. - Common Stock — Fundamental Analysis Summary
Medpace Holdings, Inc. - Common Stock (MEDP) is currently trading 533% above its Graham Number of $72.72, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 31.7x.
On financial health, MEDP shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 89.8% (sector average: 5.5%), and high leverage with a debt-to-equity ratio of 3.30.
StockPik's composite Value Score for MEDP is 37/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MEDP reports a moderate gross margin of 28.7% (sector average: 24.7%) and a strong operating margin of 21.0%.
MEDP shows revenue growing at 20% year-over-year, with earnings growing at 12%.